Medication use and in-hospital interventions for the study population
| ACS | STEMI | NSTEMI/UA | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Renal function | Severe dysfunction (n=786) | Moderate dysfunction (n=3397) | Normal/ minimally impaired (n=7591) | Severe dysfunction (n=301) | Moderate dysfunction (n=1347) | Normal/ minimally impaired (n=3068) | Severe dysfunction (n=485) | Moderate dysfunction (n=2050) | Normal/ minimally impaired (n=4523) |
| **p<0.05 across all categories of renal function within ACS, STEMI, or NSTEMI/UA subgroups; | |||||||||
| *p<0.0001 across all categories of renal function within ACS, STEMI, or NSTEMI/UA subgroups. | |||||||||
| ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; GP, glycoprotein; LMWH, low molecular weight heparin. | |||||||||
| Medications before admission (%) | |||||||||
| Aspirin, | 46.8 | 47.1 | 39.6** | 38.0 | 34.6 | 24.4** | 52.3 | 55.3 | 50.0* |
| Ticlopidine/clopidogrel | 5.2 | 4.4 | 3.1* | 4.4 | 2.7 | 1.8* | 5.6 | 5.5 | 4.1* |
| ACE inhibitors | 34.3 | 32.4 | 22.3** | 32.6 | 28.9 | 16.7** | 35.4 | 34.8 | 26.2** |
| ARBs | 5.9 | 3.6 | 2.4** | 4.1 | 2.6 | 2.1 | 7.0 | 4.2 | 2.6** |
| β Blockers | 34.5 | 31.8 | 29.0* | 27.4 | 23.1 | 18.1** | 38.9 | 37.6 | 36.4 |
| Diuretics | 38.4 | 25.4 | 11.9** | 37.0 | 21.7 | 8.6** | 39.3 | 27.9 | 14.2** |
| Statins | 19.5 | 20.9 | 21.8 | 14.3 | 16.0 | 13.7 | 22.7 | 24.2 | 27.3* |
| In-hospital medications (%) | |||||||||
| Aspirin | 91.1 | 92.0 | 94.0** | 92.7 | 93.0 | 95.3* | 90.1 | 91.3 | 93.1* |
| Ticlopidine/clopidogrel | 23.9 | 29.0 | 36.3** | 27.4 | 32.6 | 42.7** | 21.8 | 26.6 | 32.0** |
| ACE inhibitors | 55.7 | 61.6 | 55.7** | 62.1 | 69.3 | 65.6* | 51.8 | 56.4 | 49.0** |
| ARBs | 6.4 | 3.8 | 2.5** | 3.8 | 2.9 | 2.3 | 8.0 | 4.4 | 2.6** |
| β Blockers | 69.3 | 74.3 | 83.8** | 64.9 | 73.8 | 86.2** | 72.0 | 74.6 | 82.2** |
| Diuretics | 61.6 | 47.0 | 25.2** | 62.0 | 50.8 | 25.5** | 61.3 | 44.6 | 25.0** |
| Statins | 33.4 | 42.0 | 53.3** | 31.6 | 41.1 | 54.3** | 34.5 | 42.7 | 52.6** |
| LMWH | 46.7 | 49.4 | 50.1 | 47.3 | 46.6 | 45.7 | 46.4 | 51.2 | 53.1* |
| Thrombolytics | 7.2 | 13.3 | 19.5** | 15.0 | 30.1 | 44.4** | 2.3 | 2.3 | 2.7 |
| GP IIb/IIIa | 11.3 | 16.0 | 22.0** | 14.6 | 20.6 | 28.1** | 9.3 | 13.0 | 17.9** |
| In-hospital interventions | |||||||||
| PCI or CABG | 22.6 | 30.3 | 39.8** | 27.3 | 36.4 | 47.1** | 19.7 | 26.3 | 34.8** |